Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Adil save search
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical TrialExpects Release of Top-Line Data in July
Published: 2022-06-27 (Crawled : 14:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 9.24%
H: 0.0%
C: -5.38%
phase 3 topline
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
Published: 2022-06-27 (Crawled : 13:20) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 9.24%
H: 0.0%
C: -5.38%
trial phase 3
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2022-02-24 (Crawled : 14:30) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 0.0%
H: 9.0%
C: 9.0%
ad04 alcohol use disorder treatment als order trial phase 3
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published: 2021-09-30 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 0.48%
H: 3.57%
C: 2.14%
alcohol use disorder treatment phase 3 trial
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2021-08-31 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
Published: 2021-08-20 (Crawled : 15:00) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 0.32%
H: 11.82%
C: 6.71%
alcohol use disorder treatment phase 3 trial enroll
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to MarketFinancing fully funds ONWARD™ Phase 3 trial until data read-out
Published: 2021-08-05 (Crawled : 17:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: -1.93%
H: 5.11%
C: 2.76%
phase 3 trial
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
Published: 2021-07-06 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 7.76%
H: 1.17%
C: -2.93%
phase 3 trial enroll
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
Published: 2021-02-25 (Crawled : 15:00) - globenewswire.com
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: -1.6%
H: 6.82%
C: -10.71%
phase 3 trial enroll
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
Published: 2020-12-17 (Crawled : 17:00) - biospace.com/
ADIL | News | $1.72 1.18% 1.16% 140K
|
Health Technology
|
| O: 0.52%
H: 3.11%
C: -2.59%
phase 3 trial treatment enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.